Cordlife Group Ltd. is an investment holding company, which engages in the provision of cord blood and cord lining banking services. The firm's principal activities involve investment holding and the provision of cord blood banking services. Its segments include Banking and Diagnostics. The Banking segment comprises of the banking of samples such as cord blood, cord lining and cord tissue. Cord blood, cord lining and cord tissue are collected, processed, and stored in the various laboratories. The Diagnostics segment comprises diagnostic testing such as non-invasive prenatal testing service, newborn metabolic screening, newborn genetic screening, and pediatric vision screening services. Its subsidiaries include Cordlife (Hong Kong) Limited, Cordlife Stem Cell Technology Limited, Healthbaby Biotech (Hong Kong) Co., Limited, Cordlife Technologies Pte. Ltd., CS Cell Technologies Pte. Ltd., Stemlife Berhad, and Shanghai Cordlife Biomedical Research Co., Ltd.
CLIFF stock price ended at $0.15 on 火曜日, after rising 50.00%
On the latest trading day Jun 09, 2026, the stock price of CLIFF rose by 50.00%, climbing from $0.15 to $0.15. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.15 and a high of $0.15. Alongside this price increase, trading volume also rose by 589 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 356 shares were traded, amounting to a market value of approximately $38.4M.